<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04590417</url>
  </required_header>
  <id_info>
    <org_study_id>iFACT 3</org_study_id>
    <nct_id>NCT04590417</nct_id>
  </id_info>
  <brief_title>Assessment of Drug-drug Interactions Between Feminizing Hormone Therapy and Emtricitabine/Tenofovir Alafenamide Concomitantly for Pre-exposure Prophylaxis Among Transgender Women</brief_title>
  <official_title>Institute of HIV Research and Innovation (IHRI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thai Red Cross AIDS Research Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thai Red Cross AIDS Research Centre</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent studies have showed that there were significant drug-drug interactions (DDI) from&#xD;
      feminizing hormone therapy (FHT) towards emtricitabine/tenofovir disoproxil fumarate&#xD;
      (F/TDF)-based pre-exposure prophylaxis (PrEP) among transgender women (TGW). New strategies&#xD;
      for PrEP among TGW who use FHT are urgently needed. Because tenofovir alafenamide (TAF) can&#xD;
      achieve higher intracellular TFV-DP levels with lower tenofovir plasma concentrations, it is&#xD;
      promising that both plasma TFV and intracellular TFV-DP levels might not be significantly&#xD;
      affected by FHT. The current study aims to determine the pharmacokinetics DDI between FHT and&#xD;
      F/TAF-based PrEP among TGW.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two full pharmacokinetic (PK) measurements will be performed. Samples collected will include:&#xD;
      plasma for estradiol (E2), emtricitabine (FTC), tenofovir (TFV), and tenofovir alafenamide&#xD;
      (TAF) measurement; and peripheral blood mononuclear cells (PBMC) for&#xD;
      emtricitabine-triphosphate (FTC-TP) and tenofovir-diphosphate (TFV-DP) intracellular&#xD;
      quantification.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in plasma estradiol levels</measure>
    <time_frame>Measured at week 3 and week 9 of the study period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in plasma PrEP levels</measure>
    <time_frame>Week 9 through 12</time_frame>
    <description>Plasma TFV&#xD;
Plasma FTC&#xD;
Plasma TAF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in intracellular PrEP levels</measure>
    <time_frame>Week 9 through 12</time_frame>
    <description>PBMC TFV-DP levels&#xD;
PBMC FTC-TP levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma testosterone levels</measure>
    <time_frame>Week 3 through 9</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Drug Interaction</condition>
  <arm_group>
    <arm_group_label>20 HIV-negative TGW</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A single-arm prospective PK study of HIV-negative TGW taking FHT and daily PrEP.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol valerate 2 mg, cyproterone acetate 25 mg</intervention_name>
    <description>The entire study period will be approximately 1 year, which will include around 2 months of document preparation, 5 months of recruitment, 3 months of follow-up, and 2 months of data analysis.</description>
    <arm_group_label>20 HIV-negative TGW</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Thai nationality&#xD;
&#xD;
          2. Age 18-40 years old&#xD;
&#xD;
          3. Transgender women&#xD;
&#xD;
          4. HIV-negative&#xD;
&#xD;
          5. Body mass index 18.5-24.9 kg/m2&#xD;
&#xD;
          6. Calculated creatinine clearance (CrCl) ≥60 mL/min, as estimated by the Cockcroft-Gault&#xD;
             equation&#xD;
&#xD;
          7. Alanine aminotransferase (ALT) ≤2.5 x ULN&#xD;
&#xD;
          8. Signed the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known history of allergy to hormonal component to be used in the study&#xD;
&#xD;
          2. Male-to-female transgender who underwent orchiectomy&#xD;
&#xD;
          3. Use of pre-exposure prophylaxis or post-exposure prophylaxis in the past 30 days&#xD;
&#xD;
          4. Use of injectable FHT in the past 3 months&#xD;
&#xD;
          5. Evidence of current hepatitis B virus infection (HBV) - i.e. hepatitis B surface&#xD;
             antigen (HBsAg) positive&#xD;
&#xD;
          6. Evidence of current hepatitis C virus infection (HCV) - i.e. HCV antibody positive&#xD;
&#xD;
          7. Current use of any of the following:&#xD;
&#xD;
               -  Anticonvulsants: carbamazepine, felbamate, oxcarbazepine, phenytoin,&#xD;
                  phenobarbital, primidone or topiramate&#xD;
&#xD;
               -  Herbs: gingko biloba, St John's wort or milk thistle&#xD;
&#xD;
               -  Anti-infective agents: azole antifungals, macrolides, griseofulvin, protease&#xD;
                  inhibitors, rifampicin or rifabutin&#xD;
&#xD;
          8. Participant-reported active rectal infection requiring treatment&#xD;
&#xD;
          9. History of gastrointestinal tract surgery that alter gastrointestinal tract and/or&#xD;
             drug absorption&#xD;
&#xD;
         10. Alcohol or drug use that, in the opinion of the investigator, would interfere with&#xD;
             completion of study procedures&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rena Janamnuaysook, MBA</last_name>
    <role>Study Chair</role>
    <affiliation>Institute of HIV Research and Innovation (IHRI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nittaya Phanuphak, MD, PhD</last_name>
    <phone>881 8253544</phone>
    <email>nittaya.p@ihri.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rena Janamnuaysook, MBA</last_name>
    <phone>698 5164562</phone>
    <email>rena.j@ihri.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of HIV Research and Innovation (IHRI)</name>
      <address>
        <city>Bangkok</city>
        <state>Pathumwan</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nittaya Phanuphak, MD, PhD</last_name>
      <phone>+662253 0996</phone>
      <email>nittaya.p@ihri.org</email>
    </contact>
    <contact_backup>
      <last_name>Rena Janamnuaysook, MBA</last_name>
      <phone>+662253 0996</phone>
      <email>rena.j@ihri.org</email>
    </contact_backup>
    <investigator>
      <last_name>Nittaya Phanuphak, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 7, 2020</study_first_submitted>
  <study_first_submitted_qc>October 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyproterone Acetate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Cyproterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

